This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Roche Holding AG, Anthem, Inc. and Infosys Limited
by Zacks Equity Research
Roche Holding AG, Anthem, Inc. and Infosys Limited are highlighted ikn this Analyst Blog article.
Top Research Reports for Roche, Anthem & Infosys
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Anthem, Inc. (ANTM), and Infosys Limited (INFY).
AstraZeneca (AZN) Enhertu sBLA Receives FDA Priority Tag
by Zacks Equity Research
AstraZeneca's (AZN) sBLA seeks approval of Enhertu for unresectable and/or metastatic HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
Ionis' (IONS) Partner to Begin New Huntington's Disease Study
by Zacks Equity Research
Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.
Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck
by Zacks Equity Research
Roche, Pfizer, AbbVie and Merck are highlighted in this Industry Outlook article.
4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes
by Kinjel Shah
Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio.
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.
Sarepta's (SRPT) DMD Gene Therapy Study Data Fails to Impress
by Zacks Equity Research
Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.
Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies
by Zacks Equity Research
Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.
4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug
by Zacks Equity Research
AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.
PFE vs. RHHBY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. RHHBY: Which Stock Is the Better Value Option?
Blueprint Medicines (BPMC) Up 24.8% in Past 6 Months: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.
Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung
by Zacks Equity Research
Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.
Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag
by Zacks Equity Research
Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.
Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA
by Zacks Equity Research
Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.
Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%
by Zacks Equity Research
Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022
Novartis (NVS) Collaborates With BeiGene for Oncology Drug
by Zacks Equity Research
Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.
Top Research Reports for Berkshire Hathaway, Thermo Fisher & salesforce
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Thermo Fisher Scientific Inc. (TMO), and salesforce.com, inc. (CRM).
Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022
by Zacks Equity Research
Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in 2022. It expects to complete the study in four years from the study initiation date.
Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod
by Zacks Equity Research
Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.
Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
by Zacks Equity Research
The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.
Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq
by Zacks Equity Research
Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.